Synthesis, biological evaluation and in silico studies of some new analogues of 3,5-vdisubstituted thiazolidin-2,4-dione

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Parekh NM, Juddhawala KV, Rawal BM. Antimicrobial activity of thiazolyl benzene sulfonamide-condensed 2,4-thiazolidinediones derivatives. Med. Chem. Res. 22, 2737–2745 (2012).
  Google Scholar
• 2. Trotsko N, Kosikowska U, Paneth A, Plech T, Malm A, Wujec M. Synthesis and antibacterial activity of new thiazolidine-2,4-dione-based chlorophenyl thiosemicarbazone hybrids. Molecules 23, 1023 (2018).
  MedlineGoogle Scholar
• 3. Kumar H, Aggarwal N, Marwaha MG et al. Thiazolidin-2,4-dione scaffold: an insight into recent advances as antimicrobial, antioxidant, and hypoglycemic agents. Molecules 27, 6763 (2022).
  Medline CASGoogle Scholar
• 4. Fettach S, Thari FZ, Hafidi Z et al. Biological, toxicological and molecular docking evaluations of isoxazoline-thiazolidine-2,4-dione analogues as new class of anti-hyperglycemic agents. J. Biomol. Struct. Dyn. 41(3), 1072–1084 (2023).
  Medline CASGoogle Scholar
• 5. Mohd Siddique MU, Thakur A, Shilkar D et al. Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives. Eur. J. Med. Chem. 223, 113630 (2021).
  MedlineGoogle Scholar
• 6. Jiang B, Luo J, Guo S, Wang L. Discovery of 5-(3-bromo-2-(2,3-dibromo-4,5-dimethoxybenzyl)-4,5-dimethoxybenzylidene)thiazolidine-2,4-dione as a novel potent protein tyrosine phosphatase 1B inhibitor with antidiabetic properties. Bioorg. Chem. 108, 104648 (2021).
  Medline CASGoogle Scholar
• 7. Aziz HA, El-Saghier AMM, Badr M, Abuo-Rahma GEDA, Shoman ME. Thiazolidine-2,4-dione-linked ciprofloxacin derivatives with broad-spectrum antibacterial, MRSA and topoisomerase inhibitory activities. Mol. Divers. 26, 1743–1759 (2022).
  Medline CASGoogle Scholar
• 8. Akhavan M, Foroughifar N, Pasdar H, Bekhradnia A. Green synthesis, biological activity evaluation, and molecular docking studies of aryl alkylidene 2, 4-thiazolidinedione and rhodanine derivatives as antimicrobial agents. Comb. Chem. High Throughput Screen. 22, 716–727 (2019).
  Medline CASGoogle Scholar
• 9. Sethi NS, Prasad DN, Singh RK. Synthesis, anticancer, and antibacterial studies of benzylidene bearing 5-substituted and 3,5-disubstituted-2,4-thiazolidinedione derivatives. Med. Chem. 17, 369–379 (2021).
  Medline CASGoogle Scholar
• 10. Abdelgawad MA, El-Adl K, El-Hddad SSA et al. Design, molecular docking, synthesis, anticancer and anti-hyperglycemic assessments of thiazolidine-2,4-diones bearing sulfonylthiourea moieties as potent VEGFR-2 inhibitors and PPAR agonists. Pharmaceuticals (Basel) 15, 226 (2022).
  Medline CASGoogle Scholar
• 11. Taghour MS, Elkady H, Eldehna WM et al. Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in vitro anticancer evaluation and in silico studies. J. Enzym. Inhib. Med. Chem. 37, 1903–1917 (2022).
  Medline CASGoogle Scholar
• 12. Ibrahim HS, Abdelsalam M, Zeyn Y et al. Synthesis, molecular docking and biological characterization of pyrazine linked 2-aminobenzamides as new class I selective histone deacetylase (HDAC) inhibitors with anti-leukemic activity. Int. J. Mol. Sci. 23, 369 (2022).
  CASGoogle Scholar
• 13. Yu I, Choi D, Lee HK, Cho H. Synthesis, and biological evaluation of new benzylidenethiazolidine-2,4-dione derivatives as 15-hydroxyprostaglandin dehydrogenase inhibitors to control the intracellular levels of prostaglandin E₂ for wound healing. Biotechnol. Bioprocess. Eng. 24, 464–475 (2019).
  CASGoogle Scholar
• 14. Trotsko N, Golus J, Kazimierczak P et al. Synthesis and antimycobacterial activity of thiazolidine-2,4-dione based derivatives with halogenbenzohydrazones and pyridinecarbohydrazones substituents. Eur. J. Med. Chem. 189, 112045 (2020).
  Medline CASGoogle Scholar
• 15. Ratnaparkhi H, Thakar S, Bansode D. An overview of chemistry and antitubercular activity of thiazolidinediones. Sch. Acad. J. Pharm. 9, 23–31 (2020).
  CASGoogle Scholar
• 16. Elkamhawy A, Kim NY, Hassan AHE. Thiazolidine-2,4-dione-based irreversible allosteric IKK-β kinase inhibitors: optimization into in vivo active anti-inflammatory agents. Eur. J. Med. Chem. 188, 111955 (2020).
  Medline CASGoogle Scholar
• 17. Abdellatif KRA, Fadaly WAA, Kamel GM, Elshaier YAMM, El-Magd MA. Design, synthesis, modeling studies and biological evaluation of thiazolidine derivatives containing pyrazole core as potential anti-diabetic PPAR-γ agonists and anti-inflammatory COX-2 selective inhibitors. Bioorg. Chem. 82, 86–99 (2019).
  Medline CASGoogle Scholar
• 18. Asati V, Bajaj S, Mahapatra DK, Bharti SK. Molecular modeling studies of some thiazolidine-2,4-dione derivatives as 15-PGDH inhibitors. Med. Chem. Res. 25, 94–108 (2015).
  Google Scholar
• 19. Sharma RK, Younis Y, Mugumbate G et al. Synthesis and structure activity-relationship studies of thiazolidinediones as antiplasmodial inhibitors of the Plasmodium falciparum cysteine protease falcipain-2. Eur. J. Med. Chem. 90, 507–518 (2015).
  Medline CASGoogle Scholar
• 20. Ahmadi A, Khalili M, Sohrabi L, Delzendeh N, Nahri-Niknafs B, Ansari F. Synthesis and evaluation of the hypoglycemic and hypolipidemic activity of sulfonamide-benzothiazole derivatives of benzylidene-2,4-thiazolidnedione. Mini Rev. Med. Chem. 17, 721–726 (2017).
  Medline CASGoogle Scholar
• 21. Mohammed-Iqbal AK, Khan AY, Kalashetti MB, Belavagi NS, Gong YD, Khazi IAM. Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole/triazole/oxadiazole ring. Eur. J. Med. Chem. 53, 308–315 (2012).
  Medline CASGoogle Scholar
• 22. Tanaka T, Okuyama-Dobashi K, Motohashi R et al. Inhibitory effect of a novel thiazolidinedione derivative on hepatitis B virus entry. Antiviral Res. 194, 105165 (2021).
  Medline CASGoogle Scholar
• 23. Bahare RS, Ganguly S, Choowongkomon K, Seetaha S. Synthesis, HIV-1 RT inhibitory, antibacterial, antifungal and binding mode studies of some novel N-substituted 5-benzylidine-2,4-thiazolidinediones. DARU J. Pharm. Sci. 23, 6 (2015).
  MedlineGoogle Scholar
• 24. Sameeh MY, Khowdiary MM, Nassar HS, Abdelall MM, Alderhami SA, Elhenawy AA. Discovery potent of thiazolidinedione derivatives as antioxidant, α-amylase inhibitor and antidiabetic agent. Biomedicines 10, 24 (2022).
  CASGoogle Scholar
• 25. Kumar H, Deep A, Marwaha RK. Design, synthesis, in silico studies and biological evaluation of 5-((E)-4-((E)-(substituted aryl/alkyl)methyl)benzylidene) thiazolidine-2,4-dione derivatives. BMC Chem. 14, 25 (2020). •• This article is a continuation of the work from this reference.
  MedlineGoogle Scholar
• 26. Kumar H, Kumar D, Kumar P et al. Synthesis, biological evaluation and in silico ADME studies of novel series of thiazolidin-2,4-dione derivatives as antimicrobial, antioxidant and anticancer agents. BMC Chem. 16, 68 (2022). •• This article is a continuation of the work from this reference.
  Medline CASGoogle Scholar
• 27. Serban G, Stanasel O, Serban E, Bota S. 2-Amino-1,3,4-thiadiazole as a potential scaffold for promising antimicrobial agents. Drug Des. Devel. Ther. 12, 1545–1566 (2018).
  Medline CASGoogle Scholar
• 28. Moorthy P, Ekambaram SP, Perumal SS. Synthesis, characterization and antimicrobial evaluation of imidazolyl thiazolidinedione derivatives. Arab. J. Chem. 12, 413–419 (2019).
  CASGoogle Scholar
• 29. Goel A, Garima, Aggarwal N et al. Skin and soft tissue infections: current advancement in epidemiology, pathogenesis and management. J. Pure Appl. Microbiol. 17(1), 89–111 (2023).
  Google Scholar
• 30. Sharma D, Kumar S, Narasimhan B et al. Synthesis, molecular modelling and biological significance of N-(4-(4-bromophenyl) thiazol-2-yl)-2-chloroacetamide derivatives as prospective antimicrobial and antiproliferative agents. BMC Chem. 13, 46 (2019).
  MedlineGoogle Scholar
• 31. Aggarwal N, Jain S. A synthetic approach, characterization and biological evaluation of novel 5-(arylidene)-2-(5-methyl-1,3,4-thiadiazol-2-ylimino) thiazolidin-4-one derivatives. Asian J. Chem. 33, 1530–1536 (2021).
  CASGoogle Scholar
• 32. Makie SJ, Neuman KC, Maxwell A. DNA topoisomerases: advances in understanding of cellular roles and multi-protein complexes via structure-function analysis. BioEssays 43, 1–19 (2021).
  Google Scholar
• 33. Perumal P, Pandey VP, Parasuraman P. Docking studies on some novel piperidine analogues against DNA gyrase enzyme. Inventi Rapid Molecular Modeling 1, 1–4 (2014).
  Google Scholar
• 34. Ibrahim TS, Almalki AJ, Moustafa AH et al. Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: design, synthesis, ADMET prediction and molecular docking study. Bioorg. Chem. 111, 104885 (2021).
  Medline CASGoogle Scholar
• 35. Marc G, Araniciu C, Oniga SD et al. Design, synthesis and biological evaluation of new piperazin-4-yl-(acetyl-thiazolidine-2,4-dione) norfloxacin analogues as antimicrobial agents. Molecules 24(21), 3959 (2019).
  Medline CASGoogle Scholar
• 36. Ponnusamy T, Alagumuthu M, Thamaraiselvi S. Drug efficacy of novel 3-O-methoxy-4-halo disubstituted 5,7-dimethoxy chromans; evaluated via DNA gyrase inhibition, bacterial cell wall lesion and antibacterial prospective. Bioorg. Med. Chem. 26(12), 3438–3452 (2018).
  Medline CASGoogle Scholar
• 37. Durcik M, Tammela P, Barancokova M et al. Synthesis and evaluation of N-phenylpyrrolamides as DNA gyrase B inhibitors. ChemMedChem 13(2), 186–198 (2018).
  Medline CASGoogle Scholar
• 38. Ho SY, Wang W, Ng FM et al. Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria. Eur. J. Med. Chem. 157, 610–621 (2018).
  Medline CASGoogle Scholar
• 39. Abu-Melha S. Synthesis and biological evaluation of some novel 1,8-naphthyridine derivatives. Acta Chim. Slov. 64(4), 919–930 (2017).
  Medline CASGoogle Scholar
• 40. Wang J, Urban L. The impact of early ADME profiling on drug discovery and development strategy. Drug Discov. World Fall 5, 73–86 (2004).
  Google Scholar
• 41. Wang J, Urban L, Bojanic D. Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opin. Drug Metab. Toxicol. 3, 641–665 (2007).
  Medline CASGoogle Scholar
• 42. Sharma D, Kumar S, Narasimhan B et al. 4-(4-Bromophenyl)-thiazol-2-amine derivatives: synthesis, biological activity and molecular docking study with ADME profile. BMC Chem. 13, 60 (2019).
  MedlineGoogle Scholar
• 43. Wu F, Zhou Y, Li L et al. Computational approaches in preclinical studies on drug discovery and development. Front. Chem. 8, 726 (2020).
  Medline CASGoogle Scholar
• 44. Nkurunziza JB, Dukuziyaturemye P, Musabwa E, Kalluraya B. Facile synthesis, characterization and in silico docking studies of novel thiazolidine-2,4-dione-based Mannich base bearing furan/thiophene moiety as promising anti-inflammatory agents. Rwanda J. Eng. Sci. Technol. Environ. 4, 1–17 (2021). • Aided in the selection of proteins from Protein Data Bank for docking.
  Google Scholar
• 45. Cappuccino JC, Sherman N. Microbiology – A Laboratory Manual. Addison Wesley, CA, USA (1999). • Provided method of antibacteial activity.
  Google Scholar
• 46. The Indian Pharmacopoeia Commission. Pharmacopoeia of India (Volume 1). Controller of Publication, Ministry of Health Department, Government of India, New Delhi, India, 37 (2007). • Provided the nutrient media(s) composition.
  Google Scholar
• 47. Koppireddi S, Komsani JR, Avula S et al. Novel 2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamides as antioxidant and/or anti-inflammatory compounds. Eur. J. Med. Chem. 66, 305–313 (2013). • Provided the method for antioxidant activity.
  Medline CASGoogle Scholar
• 48. Jas MJS, Marimuthu G, Prithivirajan B. Hydrazone analogues: molecular modeling, synthesis, in-vivo anti-nociceptive activity and in vitro antimicrobial activity. Egypt. J. Chem. 62, 1441–1450 (2019).
  Google Scholar
• 49. Singh J, Kumar M, Mansuri R, Sahoo GC, Deep A. Inhibitor designing, virtual screening and docking studies for methyltrans-ferase: a potential target against dengue virus. J. Pharm. Bioallied Sci. 8, 188–194 (2016).
  Medline CASGoogle Scholar
• 50. Koehler MFT, Bergeron P, Blackwood EM, Bowman K et al. Development of a potent, specific CDK8 kinase inhibitor which phenocopies CDK8/19 knockout cells. ACS Med. Chem. Lett. 7, 223–228 (2016).
  Medline CASGoogle Scholar
• 51. Goel A, Aggarwal N, Jain S. Novel methodology for synthesis and computational analysis of zinc complexes of isatin derivatives and screening their biological activity. Antiinfect. Agents 20(5), 46–55 (2022).
  Google Scholar
• 52. Xi M, Chen T, Wu C et al. CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. Eur. J. Med. Chem. 164, 77–91 (2019).
  Medline CASGoogle Scholar
• 53. Gleeson MP, Hersey A, Hannongbua S. In silico ADME models: a general assessment of their utility in drug discovery applications. Curr. Top. Med. Chem. 11, 358–381 (2011).
  Medline CASGoogle Scholar
• 54. Wang JC. Untangling the Double Helix: DNA Entanglement and the Action of the DNA Topoisomerases. Cold Spring Harbor, NY, USA (2009).
  Google Scholar
• 55. Arevalo JMC, Amorim JC. Virtual screening, optimization and molecular dynamics analyses highlighting a pyrrolo[1,2-a] quinazoline derivative as a potential inhibitor of DNA gyrase B of Mycobacterium tuberculosis. Sci. Rep. 12, 4742 (2022).
  Medline CASGoogle Scholar
• 56. Maxwell A, Lawson DM. The ATP binding site of type II topoisomerases as a target for antibacterial drugs. Curr. Top. Med. Chem. 3, 283–303 (2003). • Aided in the selection of protein for docking.
  Medline CASGoogle Scholar